FDA approval of new drug regimen helps reduce risk of breast cancer recurrence for patients with early-stage disease
University of California, Los Angeles (UCLA), Health SciencesTeri Boudreaux was one of more than 5,000 women who joined a clinical trial that was looking at the benefit of adding the targeted therapy drug ribociclib to conventional hormonal therapy for the adjuvant treatment of HR-positive, HER2-negative early-stage breast cancer. I